Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 25

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
Other (expense) income, net(5)292 (5)800 Net income (loss)$15,886 $13,836 $(1,824)$(42,988)Other comprehensive income:Foreign currency translation adjustment12 14 44 9 Total comprehensive income (loss)$15,898 $13,850 $(1,780)$(42,979)Net income (loss)15,886 13,836 (1,824)(42,988)Less: Undistributed earnings allocable to participating securities(2,628)(4,208)— — Net income (loss) allocable to shares of common stock - basic and diluted13,258 9,628 (1,824)(42,988)Net income (loss) per share allocable to common stockholders:Basic$0.51 $0.58 $(0.07)$(3.88)Diluted$0.50 $0.54 $(0.07)$(3.88)Weighted-average common shares outstanding:Basic25,980,262 16,723,479 25,941,670 11,068,749 Diluted26,447,251 17,791,143 25,941,670 11,068,749 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

6

Table of Contents

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Deficit

(Amounts in thousands, except share data)

     Accumulated Series ASeries B  Additional other Preferred StockPreferred StockCommon stockpaid-inAccumulatedcomprehensiveStockholders’ SharesAmountSharesAmountSharesAmountcapitaldeficitlossdeficitBalance at December 31, 2024120,790.402 $— 437,927 $— 25,767,369 $3 $689,887 $(692,071)$(4,621)$(6,802)Issuance of common stock upon exercise of options— — — — 55,690 — 183 — — 183 Issuance of vested restricted stock units— — — — 113,042 — — — — — Stock-based compensation expense— — —